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Smoking cessation is the cornerstone of COPDmanagement, but diﬃcult to achieve in clinical practice. The eﬀect of comorbidities
on smoking cessation and risk factors for mortality were studied in a cohort of 739 COPD patients recruited in two Finnish
University Hospitals. The diagnosis of COPDwas done for the first time on average 5.5 years prior to the enrollment. Data from the
medical records and followup questionnaires (years 0, 1, 2, and 4) have been analyzed. The patients’ lung function varied greatly;
mean FEV1 58% of predicted. A total of 60.2% of men and 55.6% of women had been able to quit smoking. Alcohol abuse (OR 2.1,
95% CI 1.4–3.3) and psychiatric conditions (OR 1.8, 95% CI 1.2–2.7) were strongly related to low success rates of quitting. Among
current smokers high nicotine dependency was again explained by alcohol abuse and psychiatric conditions. Non-quitters were
younger than quitters, but their mortality rates remained significantly higher even when the model was adjusted for impairment of
lung functions and comorbidities. In conclusion, co-existing addiction and psychiatric diseases significantly decreased the success
rates in smoking cessation and increased mortality among the patients.
1. Introduction
Smoking is by far the strongest risk factor of COPD. Smoking
cessation has been shown to decelerate the progression of
the disease and reduce mortality [1, 2]. In addition, smoking
cessation is associated with a significant reduction of COPD
exacerbations [3] and hospital admissions [4]. Data on
predictors of smoking cessation relies almost entirely on
population studies [5, 6]. COPD patients on the other hand
comprise a heterogeneous group of patients who, in addition
to heavy smoking, often display a variety of addictive char-
acteristics, such as alcohol abuse [7] and certain psychiatric
disorders [8]. Except for the shown eﬃcacy of cessationmed-
ication, such as nicotine-replacement therapy, bupropion,
and varenicline [9, 10], there are sparse studies on the clinical
characteristics of COPD patients who either succeed or fail
in quitting smoking. A previous study has shown that a
significant number of COPD patients continued smoking
despite of their attempts to quit, underlining the importance
of smoking cessation programs in clinical practice [11].
Among Polish smokers simple smoking cessation advice was
shown to be more eﬃcient among patients who displayed
bronchial obstruction than among smokers with normal
lung functions, suggesting that the awareness of COPD may
improve the patient’s motivation for quitting [12]. In these
studies cumulative clinical data frommedical records was not
available.
We have followed a cohort of 739 COPD patients since
the year 2006–07 by gathering their medical records into a
single database [13]. The source data covers all health care
providers, and the participants’ medical history extends up
to 5–10 years of prior to the enrollment. The patients are
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followed for 10 years with the questionnaires mailed every
other year, currently the patients are on their fourth follow-
up year.
Using this longitudinal clinical and questionnaire data,
our aim in the present study is to report the clinical
predictors that increase the risk of failure in smoking
cessation among COPD patients. Our second aim was to find
out whether smoking cessation had an eﬀect on mortality
in this hospital-based COPD population that represented all
severity stages of the disease.
2. Study Subjects and Methods
2.1. Study Subjects. Hospital Discharge Registries were used
to identify all in- and out-patients who had visited the Pul-
monary Clinics of the Helsinki University Central Hospital
(HUCH) and Turku University Hospital during the years
1995–2006. The databases were screened by the ICD10 code
J44.8 and contained all patients between 18 to 75 years
of age. The recruitment of all the identified patients was
done through a two-phase mailing campaign. Altogether
844 patients (27%) contacted the researchers by phone and
agreed on a visit to the clinical research center in Helsinki or
Turku.
The research visits took place in years 2006–07 [13].
The participants gave their written informed consent for
collecting and merging their comprehensive medical history
from all healthcare providers who had treated them during
the past 5–10 years. The participants also agreed to continue
their followup through medical records and questionnaires
for the next 10 subsequent years. They also donated a blood
sample for DNA extraction. The health professionals exam-
ined the medical records to confirm the previously given
smoking-related COPD or chronic bronchitis diagnosis. The
diagnostic procedure described previously in detail [13]
was based on clinical outcome, smoking history ≥10 pack
years, and spirometry verification of airway obstruction. This
evaluation led to the exclusion of a total of 105 patients due to
fragmented documentation, insuﬃcient diagnostic testing,
and misclassifications.
2.2. Smoking-Related Variables. Data regarding the number
of pack years and the smoking status were evaluated at two
cross sectional time points: at the time of the diagnosis and
the enrollment to the current study. The primary source
of information for each study subject was the spirometry
form. If that data was not available, other time-labeled doc-
uments were used. If these were not available, self-reported
questionnaire data was used to acquire information about
the patient’s smoking status. Based on that data, smoking
cessation was graded as follows: (1) quitting smoking before
the diagnosis of COPD (early quitters), (2) quitting smoking
after the diagnosis, either before or during the current study
(late quitters), and (3) continued smoking throughout the
study (nonquitters). Only the combined results are reported,
in case no significant diﬀerences between the early and late
quitters could be discovered.
2.3. Clinical Variables. The reference values for FEV1 and
FVC used in Finnish clinical practice are validated in large
Finnish population samples consisting of males and females
with a wide age range [14]. “Cardiovascular diseases” consist
of patients diagnosed with one of the following diseases:
coronary, cerebrovascular, or peripheral artery occlusive
disease diagnosed by an internist. The category “diabetes”
includes patients with type 1 and 2 disease. Chronic alco-
holism, alcohol use disorder, and treatment of alcohol-use-
related disorders were all categorized as “alcohol abuse”. A
wide range of psychotic disorders and long-lasting clinical
depression and anxiety with a need for regular medication
were combined as “psychiatric condition”. The category
“cancer” included all malignant solid tumors and malignant
haematological diseases. The deaths were verified from the
National Death Registry.
2.4. Health Related Quality of life and Nicotine Dependence.
The summary scores of the participant’s general (15D) [15,
16] and airway specific (AQ20) health-related quality of
life [16] were obtained at the recruitment visit and from
the 1st follow-up questionnaire. Both questionnaires have
been validated and standardized internationally [15, 16]. The
score of 15D varies from 0 (= dead) to 1 (= full health) and in
AQ20 from 0 (= no symptoms or worries over the disease) to
20 (= full range of symptoms and worries over the disease).
The patients’ nicotine dependence was evaluated with the
Fagestro¨m nicotine dependency test (FNDT) [17]. Data for
this analysis was collected as a part of the fourth year follow-
up questionnaire. At that time point 155 patients were still
regular smokers. We were able to compute the Fagestro¨m’s
score for 140 of them.
The study approach was approved by the Coordinating
Ethics Committee of the Helsinki and Uusimaa Hospital
District, and the permission to conduct this research was
granted by the Helsinki and Turku University Hospitals.
2.5. Statistical Analysis. The statistical software package SPSS
(version 18.0) was used to compute diﬀerences in distribu-
tions of demographic and clinical variables between study
groups. Diﬀerences in continuous variables were tested using
the nonparametric Mann-Whitney U-test and in categorical
variables the Chi-square or Fisher exact tests. Multivariate
logistic regression model for smoking cessation was created
with clinically relevant continuous traits and all comorbidi-
ties as independent variables. The dependent variable was
quitting smoking either before or after COPD diagnosis, and
the independent variables included were gender, age (per
year), FEV1 (categorized into four classes >80% normal,
65–80% mild, 40–65% moderate, and <40% severe), pack
years, alcohol abuse, psychiatric condition, cardiovascular
disease, diabetes, and cancer. A similar analysis was done
for all-cause mortality: age, gender, smoking cessation, lung
functions, and comorbidities were analyzed by univariate
analysis and used in a multiple logistic regression model.
The Fagestro¨m nicotine dependency score was analyzed
with linear regression using gender, age, FEV1, alcohol
abuse, psychiatric conditions requiring medication, diabetes,
Pulmonary Medicine 3




N = 739 (%) N = 433 (%) N = 306 (%)
Men 473 (64) 285 (60.3) 188 (39.7)
NS
Women 266 (36) 148 (55.6) 118 (44.4)
Age, mean (±SD) in years 64.0 (6.8) 65.3 (6.6) 62.3 (6.8) <0.001
Duration of COPD mean (±SD) in years 5.5 (4.1) 5.8 (4.4) 5.2 (3.8) NS
BMI (kg/m2) (±SD) 26.5 (5.3) 26.5 (5.2) 26.5 (5.5) NS
Pack years (±SD) 41 (23) 43 (24) 38 (22) 0.01
Baseline mean (±SD)
FEV1% predicted 58.4 (18.9) 56.3 (18.4) 61.3 (19.3) <0.001
FVC % predicted 73.6 (18.1) 72.6 (17.9) 74.9 (18.3) 0.04
FEV1/FVC % 64.0 (13.9) 62.7 (14.4) 65.8 (13.0) 0.002
After bronchodilatation mean (±SD)
FEV1% predicted 62.1 (18.3) 60.3 (18.1) 64.4 (18.4) 0.004
FVC % predicted 77.8 (17.3) 77.4 (17.2) 78.4 (17.3) NS
FEV1/FVC % 64.4 (13.9) 63.0 (14.4) 66.4 (13.0) 0.002
N (%) of patients with
FEV1% >80 87 (12.0) 41 (9.6) 46 (15.4)
0.005 for trend
FEV1% 65–80 191 (26.4) 100 (23.5) 91 (30.5)
FEV1% 40–64 309 (42.7) 196 (46.1) 113 (37.9)
FEV1% <40 139 (18.8) 88 (20.7) 48 (16.1)
General-health-related QoL score (range 0-1) (±SD) 0.79 (0.11) 0.80 (0.10) 0.78 (0.12) 0.05
Airway specific QoL score (range 20–0) (±SD) 8.25 (5.03) 7.98 (4.77) 8.63 (5.35) NS
Comorbidities N (%)
Cardiovascular diseases 216 (29.2) 141 (32.6) 75 (24.5) 0.02
Diabetes 121 (16.4) 72 (16.7) 49 (16.1) NS
Alcohol abuse 129 (17.8) 49 (11.5) 80 (26.6) <0.001
Psychiatric disorder 177 (24.1) 75 (17.5) 102 (33.6) <0.001
Cancer 78 (10.6) 49 (11.3) 29 (9.5) NS
Deceased during the followup 114 (15.3) 52 (12.2) 62 (20.7) 0.002
1Early and late quitters combined.
and cardiovascular diseases as independent variables in the
model.
The study approach was approved by the Coordinating
Ethics Committee of the Helsinki and Uusimaa Hospital
District, and the permission to conduct this research was
granted by the Helsinki and Turku University Hospitals.
3. Results
3.1. Clinical Characteristics of the Cohort. The cohort (N =
739) represented smoking-related chronic bronchitis and
COPD of all severity stages (Table 1). FEV1 ranged from 15 to
100%,mean 58%of predicted [13]. The COPDdiagnosis was
given for the first time when the participants were on average
58 years of age. During the enrollment to the present study,
the average age was 64 years. The participants were diagnosed
on average 5.5 years prior to the enrollment, which happened
during the years 2006–07, and prospectively they have been
followed so far for 4 years. One hundred fourteen patients
had deceased during the study (annual mortality 3.8%).
3.2. Gender Diﬀerences in Smoking Behavior. In the cohort
36% of the participants were women (Table 1). There were
no significant diﬀerences in age or duration of COPD
between genders. However, the number of pack years among
men was significantly higher than among women (45 versus
33 pack years, P ≤ 0.001). When COPD was first diagnosed,
women were more frequently current smokers than men
(80% versus 68%, P < 0.001). At the time of enrollment
to the present study, the diﬀerence between genders was
diminished (40% of men and 44% of women current
smokers).
3.3. Quitting History. At the time of the enrollment, a total
of 58.6% (n = 433) patients had quitted smoking. 28% (n =
207) of the patients quitted before and 30.6% (n = 226)
after the COPD diagnosis was set. Minor, but statistically
significant, diﬀerences were observed between the groups.
The quitters were on average older (65 versus 62 years of age,
P = 0.001) and reported more pack years (43 versus 38, P =
0.011) than nonquitters (Table 1). Their disease was more
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Table 2: Independent risk factors for failure in smoking cessation
by multivariate logistic regression analysis.
Variables Adjusted OR 95% CI
Female gender 1.08 0.75–1.55






Number of pack years increased by one 0.99 0.99–1.00
Alcohol abuse 2.12 1.35–3.34∗∗
Psychiatric disorder 1.83 1.23–2.71∗∗
Cardiovascular diseases 0.78 0.53–1.15
Diabetes 1.07 0.68–1.68
Cancer 0.85 0.49–1.47
Response (nonquitter = 1, quitter = 0) ∗∗P ≤ 0.01 ∗P ≤ 0.05.
advanced (FEV1 60.3 versus 64.4% predicted, P = 0.004 and
FEV1/FVC ratio 63.0 versus 66.4, P = 0.002).
3.4. Comorbidities and Quitting. With respect to co-mor-
bidities alcohol abuse and psychiatric conditions were the
most significant risk factors associated with failure in
smoking cessation. The prevalence of alcohol abuse (26.6%
versus 11.5%P values ≤ 0.001) and psychiatric conditions
(33.6% versus 17.5%, P ≤ 0.001) were both higher among
nonquitters than quitters. Cardiovascular diseases were more
prevalent among early quitters compared to late or nonquit-
ters, 44.4% and 31.3%, respectively, P = 0.005.
Multivariate logistic regression for smoking cessation was
analyzed with clinical traits and comorbidities as indepen-
dent variables (Table 2). Of the comorbid conditions, alcohol
abuse and psychiatric conditions remained independent risk
factors for failure in smoking cessation. The two conditions
were partially overlapping. The prevalence of both con-
ditions was 14.0% (42/299) among nonquitters and 3.1%
(13/421) among quitters (P < 0.001). Gender or degree of
airway obstruction did not contribute in smoking cessation
significantly. The older a person was, the greater the chance
of success in quitting.
3.5. Mortality in the Cohort. Altogether 114 (15.3%) patients
had died by June 2011. Mortality rates were significantly
higher among nonquitters (20.7%) compared to those
among quitters (12.2%, P = 0.002). Clinical characteristics
that had an eﬀect on mortality are shown in Table 3. In
the multivariate model, failure in quitting was strongly
associated with increased mortality (OR 2.50, 95% CI 1.55–
4.03). Of the comorbidities, cancer (OR 3.08, 95% CI
1.70–5.59) and alcohol abuse (OR 2.03, 95% CI 1.14–
3.61) had an independent explanatory role in mortality.
Similarly, moderate (OR 3.2, 95% CI 1.3–8.4) and severe
(OR 5.6, 95% CI 2.5–17.5) impairment of lung function
was associated with increased mortality, but cardiovascular
diseases, diabetes, and psychiatric conditions lost the eﬀect
in the adjusted model.
3.6. Nicotine Dependence among the Current Smokers. Nico-
tine dependence was evaluated using the Fagerstro¨m nicotine
dependency test. The mean score among the patients was 4.3
(SD 2.4). The FNDT score did not correlate with FEV1 of
predicted values. Based on linear regression adjusted with
age, gender, FEV1, and comorbidities (cardiovascular dis-
eases, diabetes, and cancer), alcohol abuse was the strongest
explanatory variable for a high score (beta-value 0.260,
P = 0.003). Also psychiatric conditions had an independent
explanatory value (beta-value 0.183, P = 0.04).
4. Discussion
In the Finnish elderly population at large, smoking does not
exceed 20% among men or 10% among women [18]. In
this hospital-based COPD cohort, 40% of men and 44%
of women continued smoking on average 5.5 years after
their COPD had been diagnosed for the first time. Current
smoking was significantly more prevalent among the patients
who had alcohol abuse and/or psychiatric conditions. Com-
pared to current smokers, the quitters of the cohort were
older, reported more pack years, and had more advanced
COPD frequently accompanied by cardiovascular disease,
suggesting that the quitting takes place rather late in life and
among patients with a disabling disease.
Our findings support and expand the previous findings
made on quitting smoking in COPD [11, 12, 19]. In a large
questionnaire study (n = 58 482) made among the US
Veterans, former smokers were older and had more cardiac
comorbidities, but better mental health than current smokers
[19]. Smoking cessation is strongly recommended in patients
with cardiovascular disease and diabetes [20]. In the present
study cardiovascular disease seemed to be a strong wake-
up call to early smoking cessation and partially explained
the better quit rates among males compared to those among
females. Diabetes showed not as clear a relationship to
smoking cessation, although a similar trend was observed.
COPD patients have been reported to display a twofold
risk for depression compared to the general population [21,
22]. Even though presently largely ignored, tobacco depen-
dence among individuals with a mental illness, especially
schizophrenia, anxiety and depression, is very high [6, 8,
23, 24]. This might be explained by a robust bidirectional
connection between nicotine dependence and vulnerability
to psychopathology and susceptibility to certain psychiatric
disorders [22]. It has also been reported that heavy drinking
impairs success of quitting among COPD patients [11].
In the Finnish population over 50 years of age, hazardous
drinking has been reported in 8% of men and 2% of women
[25]. In the present COPD cohort the prevalence of alcohol
abuse was 1.8 times higher among men and 5 times higher
among women and was strongly related to nonquitting.
The Fagerstro¨m nicotine dependency test was included
in the 4th year follow-up questionnaire and thus gave us
information only from the most persistent smokers. The
FNDT score of the present COPD cohort was in accordance
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Table 3: Underlining clinical characteristics that predict mortality of the COPD patients during the four-year followup.
Variables PatientN = 739 Deceased % Crude OR 95% CI P value Adjusted OR 95% CI P value
Aging by one year 1.05 1.02–1.09 0.002 1.07 1.03–1.11 0.001
Gender
Male 466 18.0 1.00 1.00
Female 259 11.6 0.60 0.38–0.93 0.022 0.81 0.48–1.435 NS
Smoking cessation
Yes 426 12.2 1.00 1.00
No 299 20.7 1.88 1.26–2.82 0.002 2.50 1.55–4.03 <0.001
Cardiovascular diseases
No 514 13.0 1.00 1.00
Yes 211 22.3 1.91 1.26–2.89 0.002 1.52 0.94–2.46 NS
Diabetes
No 606 14.5 1.00 1.00
Yes 117 22.8 1.68 1.03–2.75 0.036 1.38 0.79–2.43 NS
Alcohol abuse
No 584 13.7 1.00 1.00
Yes 128 24.2 2.01 1.26–3.22 0.003 2.03 1.14–3.61 0.016
Psychiatric condition
No 544 14.9 1.00 1.00
Yes 175 17.1 1.18 0.75–1.87 NS 1.32 0.77–2.26 NS
Cancer
No 649 13.7 1.00 1.00
Yes 74 32.4 3.02 1.77–5.16 <0.001 3.08 1.70–5.59 <0.001
FEV1% of predicted
>80% 87 5.7 1.00 1.00
80–65% 191 9.9 1.81 0.65–5.02 NS 2.12 0.68–6.67 NS
65–40% 306 16.5 3.24 1.25–8.40 0.015 3.76 1.27–11.15 0.017
<40% 136 28.7 6.59 2.48–17.51 <0.001 8.77 2.88–26.68 <0.001
Response (dead = 1, alive = 0).
with previous studies [26]. It has been reported, however,
that low FEV1 and a high number of pack years indicate
strong nicotine dependence [23]. Thus it was somewhat
surprising that low FEV1 in the present study did not signif-
icantly associate with the nicotine dependence. The variance
found in FEV1 among these long-term persistent smokers
is, however, significantly smaller than in general population
and thus decreases our power to detect potential association.
The association between alcohol abuse and FNDT score in
our study further proves the fact that addictive behavior
cumulates [27].
Mortality was higher among nonquitters despite of their
younger age and better lung functions. The increased mor-
tality was confirmed irrespective of comorbidities, such as
cancer or cardiovascular diseases. The fact that quitters are
older, have lower lung function, more pack years, and CVD
suggests reversed causality; a “healthy smoker” eﬀect in
which patients quit smoking only when they are older and
have disabling illnesses. However, this does not directly lead
to higher mortality rates. It seems that reversed causality
is present but is confounded by the addictive profile of
nonquitters with physical and mental problems and death at
earlier age [2].
In the present study all the COPD patients (with the
recruitment rate of 27%) treated in the clinic were invited to
the study without further selection. Often in corresponding
study designs the patient cohort has been rather small [28]
or excluded relevant subgroups, such as patients with certain
comorbidities, addictions, or obesity [29]. In randomized
clinical trials, combined pharmacotherapy and counseling
seem to lead to best long-term abstinence rates [9]. Partic-
ipants’ compliance, however, is of great importance in those
types of studies [30, 31]. Therefore, patients with various
mental and substance abuse diseases—to begin with—do
not often volunteer and secondly, are generally excluded
from clinical trials. This may improve the abstinence results
of randomized trials and underestimate the significance of
addictions in COPD. In clinical practice these patients may
benefit from tight collaboration between their pulmonolo-
gist and psychiatrist when their cessation program is tailored.
Comanagement of depression and smoking cessation has
already shown to be feasible and safe. It increased the quit
attempts and the success in cessation did not increase the risk
of exacerbation of depression [32].
In addition to above-mentioned strengths our observa-
tional study design included also weaknesses. The cumulative
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clinical data was mainly based on retrospective medical
records which were not originally produced for research pur-
poses and therefore prevented us from the further dissection
of the severity of psychiatric conditions or alcohol abuse. The
smoking history reported by the patients in diﬀerent cross
sectional time points showed some inconsistencies. It seemed
diﬃcult for patients to remember when they had started and
stopped smoking especially when that had happened a long
time ago. At COPD diagnosis and during active treatment
the data was more current and thus more adequate. That
is why the data should be considered more like rough
estimates rather than precise knowledge of patients pack
years, starting and quitting dates. The Finnish Current Care
Guidelines on Tobacco dependence and cessation and on
COPD treatment are followed in the Finnish hospitals, but
unfortunately no validated stopping program has been used
[33]. In the Turku University Central Hospital patients were
systematically referred to an individual or group counseling
given by a registered nurse that improved the quit rates (66%
versus 54%) suggesting that greater counseling eﬀorts pay oﬀ
among the COPD patients.
The present study emphasizes the heterogeneous clinical
background of COPD patients, the role of coexisting diseases
on smoking cessation, and the importance of quitting in
the prognosis of COPD. New treatment options that com-
prehensively recognize patients’ mental health and addiction
profiles, and evaluate the patient’s need of psychiatric help
and/or medication, may benefit certain patient groups in
their smoking cessation and could reduce mortality in these
patient groups.
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